Dr. Ashok Srivastava, MD, Ph.D., MBA

Dr. Ashok Srivastava, MD, Ph.D., MBA

New York City Metropolitan Area
17K followers 500+ connections

Join to view profile
Trans Atlantic Therapeutics- Oncology/Hematology

About

At Trans Atlantic Therapeutics, my leadership in the clinical development of CAR-T…

Activity

Join now to see all activity

Experience

  • Trans Atlantic Therapeutics- Oncology/Hematology

    Princeton, New Jersey, United States

  • -

    London, England, United Kingdom

  • -

    Chino, California, United States

  • -

    Edinburgh, Scotland, United Kingdom

  • -

    Greater San Diego Area, California, USA

  • -

    Palo Alto, Carifornia, USA

  • -

    Flemington, New Jersey, USA

  • -

    New York City Metropolitan Area

  • -

    California, United States

  • -

    Princeton, New Jersey, Manhattan, New York, USA, Nagasaki, Japan, and New Delhi, India

  • -

    San Diego, California, USA and Tokyo, Japan

  • -

    New Jersey, United States and Tokyo, Japan

  • -

    Research Triangle Park, NC

  • -

    New Jersey, Maryland, USA

  • -

    London, Canada, USA Metropolitan Area

  • -

    Princeton, New Jersey, USA

  • -

    Irvine, California, USA and Henderson, Nevada, USA

  • -

    Global Executive Medical Director, Medical Affairs, New Jersey, USA, UK, Singapore, India, Japan;

  • -

    New Jersey, USA

  • -

    Princeton, New Jersey, USA

  • -

    New Jersey, USA, Tokyo and Osaka, Japan

  • -

    New Jersey and New York, USA

  • -

    Montevale, New Jersey, USA

  • -

    Walter Reed National Military Medical Center, Washington DC, USA

  • -

    Nagasaki School of Medicine, Nagasaki, Japan

Education

  • Harvard University Graphic

    Harvard University

    -

    Re-fresher course in medical and clinical oncology certification

  • - Present

  • Activities and Societies: Nagasaki Cancer Hospital

  • -

    Activities and Societies: Medical Oncology and Hematology. Pharmaceutical Business Management • School of Medicine Nagasaki University School of Medicine, Nagasaki, Japan • Rutgers University Business School of Management, New Jersey, USA • Czechoslovak Academy of Medical Sciences, Prague, Czechoslovakia • All India Institute of Medical Sciences, New Delhi, India

    Board Certification in Medical Affairs
    Breast cancer, Lung cancer, Supportive care,
    Board member of cancer drug development
    Board Member of Calidi Biotherapeutics
    Board Member Carcinotech Ltd, UK

  • Activities and Societies: Onco-virology

  • -

  • •American Association of Clinical Oncology
    • Head and Neck cancer Foundation
    • Breast Cancer Foundation
    • International Society of Lung Cancer
    • American Society of Hematology
    • Foundation of Chemotherapy
    • Royal College of Pathologists, UK
    • Indo American Cancer Association, US based Oncologists of Indian Heritage.

Licenses & Certifications

Publications

  • CAR-T Cell Therapy for Relapsed/Refractory Hematologic Malignancies Adverse Events in Risks and Maximizing Safety: Ashok Srivastava, MD, Ph.D. and Pallavi Dhillon, PharmD, Ph.D.;

    In Press

  • A Phase 1b, to Investigate the Safety, Pharmacokinetics and Antitumor Activities of RAF Dimer Inhibitor Lifirafenib in Combination with MEK inhibitor Mirdametinib in Patients with Advanced or Refractory Solid Tumors

    ASCO

  • Integrated Results of Two Multicenter, Randomized, Placebo Controlled, Double Blind, Phase 3 Trials of Single-Dose Intravesical Apaziquone Immediately Following Resection in Patients with Non-Muscle Invasive Bladder Cancer

    AUA-2016, San Diego

  • CAR-T Cell Therapy for Relapsed/Refractory Hematologic Malignancies: Ashok Srivastava, MD, Ph.D., MBA....In Press 2024

    -

Patents

  • Inactivated Japanese Encephalitis Vaccine

    US Patent No.: US 6,309,650 B1

    Attenuated Japanese Encephalitis Virus Adapted to Vero Cell and A Japanese Encephalitis Vaccine-

    To prevent Japanese encephalitis disease!!!

    See patent

  • Recombinant Dengue Virus Vaccine

    US Patent Number: 6,117,640

    A recombinant protein encompassing a C-terminal protion from the structural envelope glycoprotein and an N-terminal portion from non-structural protein one of dengue type 2 virus was expressed in Escherichia coli as a fusion protein with Staphylococcal protein A. The recombinant protein was found to provide protection against lethal challenge with dengue 2 virus.

    See patent

Honors & Awards

  • Licensed Pilot

    -

  • Award

    -

    • United Nation Fellow Award
    • Best Oncologist of USA, 2017
    • Best Oncologist of USA, 2011
    • Clinical Fellow award, Walter Reed Medical Center, Washington DC, USA
    • Best Clinical Fellow Award: Walter Reed Army Institute of Research, Washington DC, USA
    • Clinical Fellowship of Ministry of Health, Japan
    • Fellow, National Academy of Sciences, Washington, DC, USA

Languages

  • Japanese

    Full professional proficiency

More activity by Dr. Ashok

View Dr. Ashok’s full profile

  • See who you know in common
  • Get introduced
  • Contact Dr. Ashok directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More